Teyi Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 31.1081 million yuan, down 18.15% from the same period last year. The company's total operating revenue was 393 million yuan, down 19.92% year-on-year; net cash inflow from operating activities was 85.3908 million yuan, down 41.60% year-on-year. The company's latest asset-liability ratio was 27.34%, gross margin was 56.92%, ROE was 1.75%, and diluted earnings per share was 0.06 yuan.
Teyi Pharmaceutical Group Co LtdNet profit down 18.15% and revenue down 19.92% year-on-year.
